Tirzepatide dosage in clinical trials

Doses in published trials

Arms as registered

Verbatim arm text from ClinicalTrials.gov, for the 40 highest-phase and most recent of 106 matching studies. Only arms naming Tirzepatide and a dose are shown.

1. NCT07829198 · Phase 3 · Not yet recruiting · n=70

   Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

   • Tirzepatide — Participants will receive tirzepatide once weekly by subcutaneous injection, self-administered at home. Treatment will start at 2.5 mg once weekly, with up-titration in 2.5 mg increments every 4 weeks (5 mg, 7.5 mg, 10 mg, 12.5 mg, up to 15 mg), according to tolerability, up to the maximum tolerated dose or 15 mg once weekly. Treatment will continue for a total of 52 weeks.

2. NCT07738276 · Phase 3 · Not yet recruiting · n=60

   Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

   • Tirzepatide — Participants receive tirzepatide via prefilled subcutaneous injection pen once weekly, in addition to standard heart failure therapy. Starting dose is 2.5 mg once weekly for 4 weeks, titrated based on tolerability every 4 weeks up to a maximum of 10 mg once weekly, continued through month 6.

3. NCT07635953 · Phase 3 · Not yet recruiting · n=296

   New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes

   • Group A (triple combination intensive therapy group) — Tirzepatide, empagliflozin, and pioglitazone treatment. 1) Initiate with Tirzepatide 2.5 mg once weekly (qw) + Empagliflozin 10 mg once daily (qd) + Pioglitazone 15 mg once daily (qd); 2) After 1 month, adjust Tirzepatide to 5.0 mg qw + Empagliflozin 20 mg qd + Pioglitazone 30 mg qd; 3) After 1 month, adjust Tirzepatide to 7.5 mg qw + Empagliflozin 20 mg qd + Pioglitazone 30 mg qd. 4) After 1 month, adjust Tirzepatide to 10.0 mg qw + Empagliflozin 20 mg qd + Pioglitazone 30 mg qd; 5) If blood glucose remains uncontrolled after 1 month, add basal insulin therapy.
   • Group B (standard therapy group) — Metformin-based treatment is recommended when not contraindicated. 1) Initiate with Metformin monotherapy, titrate to the target dose of 1000 mg twice daily (bid) within 1 month or to the maximum tolerated dose (if Metformin is not tolerated, switch to Linagliptin 5 mg qd); 2) After 1 month, if blood glucose is not controlled, add a second antidiabetic drug, Empagliflozin 20 mg qd; 3) After 1 month, if blood glucose remains uncontrolled, add Tirzepatide 2.5 mg qw; 4) After 1 month, if blood glucose remains uncontrolled, adjust Tirzepatide to 5.0 mg qw; 5) After 1 month, if blood glucose remains uncontrolled, adjust Tirzepatide to 7.5 mg qw; 6) After 1 month, if blood glucose remains uncontrolled, adjust Tirzepatide to 10.0 mg qw.

4. NCT07284511 · Phase 2/Phase 3 · Recruiting · n=105

   A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

   • Tirzepatide group — Participants randomized to this arm receive once-weekly subcutaneous tirzepatide in addition to use of the Tandem Control-IQ insulin pump and Dexcom G7 continuous glucose monitor. Tirzepatide is initiated at 2.5 mg weekly and increased by 2.5 mg every 4 weeks to a target dose of 10 mg weekly or the maximally tolerated dose. Dose escalation may be delayed or reduced if participants experience intolerable gastrointestinal symptoms. During Weeks 1-26, participants continue standard carbohydrate counting for all meals. Beginning in Week 27, participants stop entering carbohydrate amounts into the pump (no meal announcements) for six weeks while continuing tirzepatide at their maintenance dose. Throughout the intervention, participants undergo regular safety assessments, remote glucose data reviews, insulin-pump parameter adjustments as needed, and scheduled in-person visits to monitor metabolic, cardiovascular, and patient-reported outcomes.

5. NCT07481747 · Phase 3 · Recruiting · n=2,539

   Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

   • Arm 1: Tirzepatide 5 mg once weekly + lifestyle intervention
   • Arm 2: Tirzepatide 10 mg once weekly + lifestyle intervention
   • Arm 3: Tirzepatide 15 mg once weekly + lifestyle intervention

6. NCT07834398 · Phase 3 · Completed · n=150

   Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes

   • Tirzepatide Group — Includes 50 non-diabetic obese participants receiving Tirzepatide 15 mg subcutaneous once weekly for 24 weeks

7. NCT06918405 · Phase 3 · Active, not recruiting · n=440

   Efficacy and Safety of Tirzepatide for Weight Management

   • Tirzepatide arm — All the included patients in both the diabetic and nondiabetic groups will receive the same intervention of tirzepatide at a dose of 15 mg administered subcutaneously once a week in addition to lifestyle modification. Initially, tirzepatide will be started with a dose of 2.5 mg once weekly subcutaneous injection for the first 4 weeks. After the stabilization period of the drug, the dose will be increased to 5 mg after 4 weeks, 7.5 mg after 8 weeks, 10 mg after 12 weeks, 12.5 mg after 16 weeks and finally 15 mg after 20 weeks.

8. NCT06246799 · Phase 3 · Recruiting · n=256

   Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

   • Group IC — Tirzepatide starting at 2.5mg weekly titrated to 15mg weekly (2.5 month 1, 5mg month 2, 10mg month 3 and 15mg at month 4) with Pioglitazone beginning at 15mg daily and ending at 45mg daily (15mg month 1, 30mg month 2 and 45mg at month 3 onwards).
   • Group IA — Tirzepatide will be started at 2.5mg and increased to 15mg by month 4. At month 6, Pioglitazone will be added to the Tirzepatide, 15 mg daily.
   • Group 1B — Pioglitazone will be started at 15mg and increased to 45 mg by month 3. At month 6, tirzepatide 2.5mg will be started and increased weekly as tolerated.

9. NCT06162715 · Phase 2/Phase 3 · Active, not recruiting · n=30

   GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

   • Tirzepatide Group — Participants in the TRZ cohort will initiate a standardized dose titration as described in the package insert. Participants will begin TRZ at 2.5 mg for four weeks and then increase by 2.5 mg every 4 weeks to a maximum dose of 15 mg. If subjects experience intolerable GI symptoms, they will be allowed to decrease to a lower dose by 2.5 mg for 2 weeks, at which point another attempt at an increased dose will be trialed. Should patients not tolerate a higher dose a second time, they will have the dose again lowered by 2.5 mg and kept at the lower dose for the remainder of the study, except for patients who do not tolerate two attempts at 5 mg. For patients who fail to titrate to at least 5 mg TRZ, a third attempt at an increased dose will be attempted 4 weeks after the second decrease in dose. These patients will then remain on 5 mg for the remainder of the intervention period. All participants receiving TRZ will be pooled in terms of outcomes measures.

10. NCT06131437 · Phase 3 · Completed · n=809

    A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

    • Tirzepatide 15 mg — Participants will receive 15 mg tirzepatide subcutaneously once-weekly (dose escalation period of 20 weeks) for up to 84 weeks.

11. NCT06047548 · Phase 3 · Completed · n=441

    A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

    • Tirzepatide 5 milligram (mg) — Participants will receive tirzepatide subcutaneously (SC).

12. NCT05963022 · Phase 3 · Completed · n=206

    A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

    • 5 Milligram (mg) Tirzepatide — Participants received 5 mg of tirzepatide administered as subcutaneous (SC) injection via a single-dose pen (SDP) once weekly (QW) for 40 weeks. The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks until the maintenance dose of 5 mg was reached.
    • 10 mg Tirzepatide — Participants received 10 mg of tirzepatide administered as SC injection via a SDP QW for 40 weeks. The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg) until the maintenance dose of 10 mg was reached.
    • 15 mg Tirzepatide — Participants received 15 mg of tirzepatide administered as SC injection via a SDP QW for 40 weeks. The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5 mg to 15 mg) until the maintenance dose of 15 mg was reached.

13. NCT05822830 · Phase 3 · Completed · n=751

    A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

    • 15 mg or MTD - Tirzepatide — Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW) for 4 weeks, then the dose was increased by 2.5 mg every 4 weeks (2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg) up to 15 mg QW or maximum tolerated dose \[MTD (10 mg or 15 mg)\] until Week 72.

14. NCT05691712 · Phase 3 · Completed · n=257

    A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

    • 5 Milligram (mg) Tirzepatide — Participants received 5 mg of tirzepatide administered as subcutaneous (SC) injection via a single-dose injection pen (SDP) once weekly (QW) for 40 weeks. The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks until the maintenance dose of 5 mg was reached.
    • 10 mg Tirzepatide — Participants received 10 mg of tirzepatide administered as SC injection via a SDP QW for 40 weeks. The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg) until the maintenance dose of 10 mg was reached.
    • 15 mg Tirzepatide — Participants received 15 mg of tirzepatide administered as SC injection via a SDP QW for 40 weeks. The starting dose of tirzepatide was 2.5 mg QW, which increased by 2.5 mg every 4 weeks (2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5 mg to 15 mg) until the maintenance dose of 15 mg was reached.

15. NCT05412004 · Phase 3 · Completed · n=469

    Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

    • Tirzepatide MTD_GPI1 — Participants not on positive airway pressure (PAP) therapy received a maximum tolerated dose (MTD) of 10 milligrams (mg) or 15 mg of Tirzepatide once weekly (QW) as a subcutaneous (SC) injection for 52 weeks, including the initial dose escalation by 2.5 mg every 4 weeks
    • Tirzepatide MTD_GPI2 — Participants who are on PAP therapy received an MTD of 10 mg or 15 mg of Tirzepatide QW as an SC injection for 52 weeks, including the initial dose escalation by 2.5 mg every 4 weeks

16. NCT05024032 · Phase 3 · Completed · n=210

    A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

    • 10 Milligrams (mg) Tirzepatide — Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).
    • 15 mg Tirzepatide — Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.

17. NCT04844918 · Phase 3 · Completed · n=267

    A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

    • 10 Milligrams (mg) Tirzepatide — Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).
    • 15 mg Tirzepatide — Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.

18. NCT04847557 · Phase 3 · Completed · n=731

    A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

    • Tirzepatide — Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW) and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or maximum tolerated dose (MTD) tolerated by the participant (5 mg QW or 10 mg QW).

19. NCT04657003 · Phase 3 · Completed · n=938

    A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

    • 10 milligrams (mg) Tirzepatide — 10 mg Tirzepatide administered subcutaneously (SC) once weekly (QW)
    • 15 mg Tirzepatide — 15 mg Tirzepatide administered SC QW

20. NCT04660643 · Phase 3 · Completed · n=783

    A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

    • Tirzepatide (lead-in) — Participants received weekly doses of tirzepatide subcutaneously (SC) for 36 weeks, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks, as tolerated, up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg.
    • Tirzepatide MTD — Participants continued tirzepatide MTD (either 10 mg or 15 mg) for an additional 52 weeks.

21. NCT04657016 · Phase 3 · Completed · n=579

    A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

    • Tirzepatide — Participants received weekly doses of tirzepatide subcutaneously (SC) for 72 weeks, starting at 2.5 milligrams (mg) for 4 weeks. Subsequently, the dose was increased by 2.5 mg every 4 weeks up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg.

22. NCT04537923 · Phase 3 · Completed · n=1,428

    A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

    • 5 mg Tirzepatide — 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
    • 10 mg Tirzepatide — 10 mg tirzepatide administered SC once a week.
    • 15 mg Tirzepatide — 15 mg tirzepatide administered SC once a week.

23. NCT04255433 · Phase 3 · Completed · n=13,299

    A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

    • Tirzepatide - Maximum Tolerated Dose (MTD) — Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered as subcutaneous (SC) injection once weekly (QW) and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or MTD tolerated by the participant (5 mg QW or 10 mg QW) for up to 5 years.

24. NCT04093752 · Phase 3 · Completed · n=917

    A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

    • 5 mg Tirzepatide — Participants received 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW).
    • 10 mg Tirzepatide — Participants received 10 mg tirzepatide administered SC QW.
    • 15 mg Tirzepatide — Participants received 15 mg tirzepatide administered SC QW.

25. NCT04184622 · Phase 3 · Completed · n=2,539

    A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

    • 5 mg Tirzepatide — * Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks until reaching a dose of 5 mg, which was then maintained up to week 72. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the 5 mg tirzepatide dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.
    • 10 mg Tirzepatide — * Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks until reaching a dose of 10 mg, which was then maintained up to week 72. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the 10 mg tirzepatide dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.
    • 15 mg Tirzepatide — * Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 mg and increasing by 2.5 mg every 4 weeks until reaching a dose of 15 mg, which was then maintained up to week 72. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the 15 mg tirzepatide dose SC QW until week 176. * Safety Follow-up Period: Participants who had completed or discontinued the primary treatment period were followed for safety for 4 weeks (weeks 72 - week 76), and those who had completed or discontinued the additional treatment period (prediabetes at randomization) were followed for 17 weeks (week 176 - week 193). No treatment was administered during this period.

26. NCT04039503 · Phase 3 · Completed · n=475

    A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

    • 5 mg Tirzepatide — 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
    • 10 mg Tirzepatide — 10 mg tirzepatide administered SC once a week.
    • 15 mg Tirzepatide — 15 mg tirzepatide administered SC once a week.

27. NCT03987919 · Phase 3 · Completed · n=1,879

    A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

    • 5 mg Tirzepatide — 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
    • 10 mg Tirzepatide — 10 mg tirzepatide administered SC once a week.
    • 15 mg Tirzepatide — 15 mg tirzepatide administered SC once a week.

28. NCT03954834 · Phase 3 · Completed · n=478

    A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

    • 5 mg Tirzepatide — Participants received 5 milligrams (mg) of tirzepatide as subcutaneous injection once a week.
    • 10 mg Tirzepatide — Participants received 10mg of tirzepatide as subcutaneous injection once a week.
    • 15 mg Tirzepatide — Participants received 15mg of tirzepatide as subcutaneous injection once a week.

29. NCT03861052 · Phase 3 · Completed · n=636

    A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

    • 5 mg Tirzepatide — Participants received 5 milligram (mg) tirzepatide administered subcutaneously (SC) once weekly for 52 weeks.
    • 10 mg Tirzepatide — Participants received 10 mg tirzepatide administered SC once weekly for 52 weeks.
    • 15 mg Tirzepatide — Participants received 15 mg tirzepatide administered SC once weekly for 52 weeks.

30. NCT03882970 · Phase 3 · Completed · n=1,444

    A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

    • 5 mg Tirzepatide — 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
    • 10 mg Tirzepatide — 10 mg tirzepatide administered SC once a week.
    • 15 mg Tirzepatide — 15 mg tirzepatide administered SC once a week.

31. NCT03861039 · Phase 3 · Completed · n=443

    A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

    • 5 mg Tirzepatide — 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week. Participant received the following pre-treatment oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
    • 10 mg Tirzepatide — 10 mg tirzepatide administered SC once a week. Participant received the following pre-treatment oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
    • 15 mg Tirzepatide — 15 mg tirzepatide administered SC once a week. Participant received the following pre-treatment oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.

32. NCT03730662 · Phase 3 · Completed · n=2,002

    A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

    • 5 mg Tirzepatide — 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
    • 10 mg Tirzepatide — 10 mg tirzepatide administered SC once a week.
    • 15 mg Tirzepatide — 15 mg tirzepatide administered SC once a week.

33. NCT07832084 · Phase 4 · Not yet recruiting · n=60

    Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s

    • Low dose, alternate frequency — GLP-1 dose reduction to lower-dose, alternate frequency. Participants on semaglutide at enrollment will gradually reduce their dose from 2.4mg to 1.7mg to 1.0mg to 0.5mg once a week to 0.5mg every other week. Participants on tirzepatide at baseline will gradually reduce their dose from 15mg to 12.5mg to 10mg to 7.5mg to 5mg once a week to 5mg every other week. Dose reductions are scheduled every 4 weeks.
    • Non-incretin based therapy — After gradually reducing GLP-1 therapy, participants will start phentermine with topiramate. Participants will reduce their semaglutide or tirzepatide dosage following the schedule of the "low dose, alternate frequency" arm until either semaglutide is 0.5mg once a week or tirzepatide is 5mg once a week. Participants will then start phentermine at 15mg once a day. Four weeks later, they will add topiramate at 25mg once a day. Four weeks later, they will increase the phentermine dose to 30mg once a day. Four weeks later, they will increase topiramate to 50mg once a day. Participants who cannot tolerate or have contraindications to phentermine will be offered bupropion + naltrexone. Dosages for bupropion would start at 75mg twice a day (maintenance dose 150mg twice a day). Dosages for naltrexone would start at 25mg per day. For subjects where a review by the PI or Co-I suggest a favorable benefit/risk profile, an option would be provided to increase naltrexone to 25mg twice per day.

34. NCT07715929 · Phase 4 · Not yet recruiting · n=710

    Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients

    • Tirzepatide + Lifestyle Intervention — Standardized lifestyle intervention and standard AF management plus once-weekly subcutaneous tirzepatide, initiated after randomization and continued through Week 52. Tirzepatide titration (per NMPA label): * Weeks 1-4: 2.5 mg once weekly (initiation) * Weeks 5-16: escalate by 2.5 mg every 4 weeks (5 mg → 7.5 mg → 10 mg) * Weeks 17-52: maintenance 10 mg once weekly, up-titratable to 15 mg (maximum dose 15 mg)

35. NCT07756359 · Phase 4 · Not yet recruiting · n=20

    Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

    • Tirzepatide — Treatment will start at 2.5 mg once weekly. After 4 weeks, the dose will be increased to 5 mg once weekly. After another 4 weeks, the dose will be increased to 7.5 mg once weekly for 4 weeks.
    • Optimized Standard of Care anti-diarrheal therapy — Optimized regimen of loperamide 2 mg orally every 6 hours as needed for increased frequency or diphenoxylate/atropine can be given 2 mg orally every 6 hours. When using either or both therapies in combination the participant should not exceed a maximum dose of 16 mg orally within 24 hours. For participants with continued or worsening high bowel frequency for \>2 weeks, transition to active therapy with tirzepatide will be offered at week 4. Tirzepatide treatment would begin as 2.5 mg once weekly. After 4 weeks, the dose will be increased to 5 mg once weekly. After another 4 weeks, the dose will be increased to 7.5 mg once weekly for 4 weeks.

36. NCT07191873 · Phase 4 · Recruiting · n=60

    Tirzepatide in Idiopathic Intracranial Hypertension Trial

    • Tirzepatide — Participants receive Tirzepatide weekly on the following dose schedule for a year: Dosage Treatment time 2.5mg/0.5mL: Month 1 (4 Weeks) 5mg/0.5mL: Month 2 (4 Weeks) 7.5mg/0.5mL: Month 3 (4 Weeks) 10mg/0.5mL: Month 4 (4 Weeks) 12.5mg/0.5mL: Month 5-6 15mg/0.5 mL: Month 7-12
    • Placebo — Participants receive Tirzepatide Placebo weekly on the following dose schedule for a year: Dosage Treatment time 2.5mg/0.5mL: Month 1 (4 Weeks) 5mg/0.5mL: Month 2 (4 Weeks) 7.5mg/0.5mL: Month 3 (4 Weeks) 10mg/0.5mL: Month 4 (4 Weeks) 12.5mg/0.5mL: Month 5-6 15mg/0.5 mL: Month 7-12

37. NCT07554638 · Phase 4 · Recruiting · n=50

    Incretin Therapies in Obesity-related HFpEF

    • Tirzepatide — After a 3-month control period, participants will be prescribed tirzepatide and undergo serial plasma volume measurement and body composition analysis. Participants will be prescribed tirzepatide under the brand name Monjauro if they have diabetes, and under the brand name Zepbound if they do not have diabetes. All participants will be initiated on an initial dose of 2.5 mg injected subcutaneously in the thigh or abdomen every week on same day and at the same time.

38. NCT07630454 · Phase 4 · Not yet recruiting · n=602

    Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF

    • Tirzepatide + Lifestyle Intervention — Participants receive subcutaneous tirzepatide once weekly for 12 months in addition to guideline-directed lifestyle intervention. Dose escalation: 2.5 mg/week for weeks 1-4; 5 mg/week for weeks 5-8; 7.5 mg/week for weeks 9-12; 10 mg/week from week 13 onward (target); may be escalated to 15 mg/week if tolerated. All participants additionally receive a structured lifestyle intervention identical to the control arm.

39. NCT07555730 · Phase 4 · Not yet recruiting · n=400

    AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)

    • Tirzepatide — Participants will be randomized to receive tirzepatide 5 mg treatment for 52 weeks.

40. NCT07354880 · Phase 4 · Not yet recruiting · n=30

    Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease

    • Trizepatide — Tirzepatide (Munjaro), starting dose 2,5 mg subcutaneous weekly for 4 weeks, dosage increased monthly for 2.5 mg according to study protocol, based on clinical response and tolerability.